Scheme Pending
Eli Lilly and Company acquisition of Centessa Pharmaceuticals
US$6.3bn equity value
Announced 31 Mar 2026 · NASDAQ: CNTA · US$38.00 cash per share
Advisers
Centessa Pharmaceuticals
Target
- Financial adviser
- Legal adviser
- Fairness opinion
- Target
- Centessa Pharmaceuticals
- Acquirer
- Eli Lilly and Company
- Target based in
- United Kingdom
- Buyer based in
- United States
- Structure
- Scheme of arrangement
- Sector
- Biotech
- Tags
- Biotech, Pharma
In the league tables
Similar deals
- Biogen acquisition of Apellis Pharmaceuticals Mar 2026 · US$5.6bn · Biotech
- BioMarin acquisition of Amicus Therapeutics Dec 2025 · US$4.8bn · Biotech
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- Servier acquisition of Day One Biopharmaceuticals Mar 2026 · US$2.5bn · Biotech
Sources
- 2026 Centerview Partners: Lead financial advisor to Centessa Pharmaceuticals on its acquisition by Eli Lilly centerviewpartners.com
- Mar 2026 Kirkland Advises Eli Lilly on Agreement to Acquire Centessa Pharmaceuticals for up to $7.8 Billion kirkland.com
- Mar 2026 Jefferies: Joint Financial Advisor: Sale to Eli Lilly jefferies.com
- 31 Mar 2026 Press release (EX-99.1, exhibit), Ashley Hennessey; gentry_ashley_jo@lilly.com; sec.gov
- 31 Mar 2026 Goodwin Advises Centessa on Definitive Agreement to Be Acquired by Lilly for Up to $7.8 Billion goodwinlaw.com
- 31 Mar 2026 Press release (PR Newswire), Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders prnewswire.com
- 7 May 2026 Definitive merger proxy statement (DEFM14A), Centessa Pharmaceuticals plc sec.gov




